Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208272 | 0.96 | TSHR (0.49) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL5208279 | 0.96 | TSHR (0.49) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL5213527 | 0.96 | TSHR (0.49) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL26075115 | 0.95 | TSHR (0.47) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL21400551 | 0.80 | LMNA (0.47) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL12475851 | 0.79 | GAA (0.47) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL3522990 | 0.78 | LMNA (0.45) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL30059612 | 0.78 | MAPT (0.53) | TSHRLMNAGAAMAPTAR | |
| SCHEMBL3521800 | 0.76 | LMNA (0.44) | TSHRLMNAGAAMAPTNOS2 | |
| SCHEMBL7889801 | 0.75 | GAA (0.38) | TSHRLMNAGAAMAPTAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| US-7071185-B2 | 1,2,3,4,7,8-hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | WYETH | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154920-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij] quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR7, HTR1A | TSHR 256/4885LMNA 3340/4885GAA 2366/4885 |
| US-20040019040-A1 | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | HTR2C, HTR1A, HTR7 | TSHR 336/4885LMNA 3303/4885GAA 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.